SynthesisFrontiers in endocrinology2023
Prevalence of osteoporosis in patients with nephrolithiasis and
Synthesis in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Gut microbiota: a novel key player in urinary stone formation - from oxalate metabolism to systemic regulation.Gut microbes · 2026Review
- Phosphate handling as a determinant of osteoporosis in primary hyperparathyroidism.Endocrine connections · 2026Article
- Assessing causality between kidney stones and osteoporosis: strengths, gaps, and future needs.International urology and nephrology · 2025Article
- Exploring the link between nephrolithiasis and osteoporosis: implications for clinical management and treatment advancements.International urology and nephrology · 2025Article
- The association between the presence of kidney stones and the risk of developing osteoporosis: a NHANES-based cross-sectional study and Mendelian randomization analysis.International urology and nephrology · 2025Observational
- Exploring the association between osteoporosis and kidney stones: a clinical to mechanistic translational study based on big data and bioinformatics.Biology direct · 2025Article
- Bone mineral density and sex hormone binding globulin as potential mediators of the causal effect of urolithiasis on osteoporosis risk: a Mendelian randomization.Frontiers in endocrinology · 2025Article
- Aortic Calcification in Patients with Nephrolithiasis: A Cross-Sectional Case-Control Study.Medical journal of the Islamic Republic of Iran · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Nephrolithiasis is thought to be a risk factor for osteoporosis, but data assessing if osteoporosis predisposes to the risk of nephrolithiasis are lacking. The present study aims to investigate whether patients with nephrolithiasis have a prominently higher prevalence of osteoporosis than the controls and Methods: Four databases were used to detect the eligible studies. We calculated the relative risk (RR) with a 95% confidence interval (CI) to assess the combined effect. The methodologies for conducting this study followed the PRISMA guidelines and were registered in the PROSPERO (ID: CRD42023395875). Results: Nine case-control or cohort studies with a total of 454,464 participants were finally included. Combined results indicated that there was a significantly higher prevalence of osteoporosis in patients with nephrolithiasis as compared to the general population without nephrolithiasis (overall RR from six studies= 1.204, 95%CI: 1.133 to 1.28, Conclusions: The present study highlighted a significantly high prevalence of osteoporosis in patients with nephrolithiasis and Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42023395875.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.